Maia Wealth LLC raised its stake in Cencora, Inc. (NYSE:COR – Free Report) by 7.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,960 shares of the company’s stock after buying an additional 551 shares during the quarter. Maia Wealth LLC’s holdings in Cencora were worth $1,788,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in COR. Capital Wealth Planning LLC raised its stake in shares of Cencora by 68.2% during the 4th quarter. Capital Wealth Planning LLC now owns 1,537 shares of the company’s stock worth $345,000 after purchasing an additional 623 shares in the last quarter. Fisher Asset Management LLC raised its position in Cencora by 17.7% during the fourth quarter. Fisher Asset Management LLC now owns 1,091 shares of the company’s stock valued at $245,000 after acquiring an additional 164 shares in the last quarter. SVB Wealth LLC acquired a new stake in Cencora in the fourth quarter valued at approximately $431,000. Dynasty Wealth Management LLC bought a new stake in Cencora in the fourth quarter worth approximately $1,871,000. Finally, QRG Capital Management Inc. increased its stake in shares of Cencora by 0.6% during the 4th quarter. QRG Capital Management Inc. now owns 20,142 shares of the company’s stock worth $4,526,000 after purchasing an additional 122 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.
Insiders Place Their Bets
In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.80% of the company’s stock.
Analysts Set New Price Targets
Get Our Latest Analysis on COR
Cencora Stock Up 1.8 %
Shares of COR stock opened at $253.49 on Friday. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm has a market cap of $49.16 billion, a PE ratio of 36.06, a price-to-earnings-growth ratio of 1.31 and a beta of 0.49. The stock has a 50 day moving average of $241.71 and a 200-day moving average of $237.84.
Cencora (NYSE:COR – Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.
Cencora Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.87%. The ex-dividend date is Friday, February 14th. Cencora’s dividend payout ratio (DPR) is presently 31.29%.
About Cencora
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
See Also
- Five stocks we like better than Cencora
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- Dividend Capture Strategy: What You Need to Know
- MarketBeat Week in Review – 02/24 – 02/28
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.